Ansell shares (ASX: ANN) jumped to a multi-year high of A$41.93 on Monday following impressive FY26 results, only to close at A$38.24 as RBC Capital Markets downgraded the stock on valuation grounds despite raising its price target.
The Ansell share price closed Monday’s session up 9.57% at A$38.24, well off the intraday high of A$41.93 that marked the highest level in several years. The spike came on the back of the company’s full-year results announcement, which showed adjusted earnings per share of US148.6 cents for the year ended 30 June 2026, landing near the top of guidance and representing roughly 18% growth on an organic, constant-currency basis. Revenue reached approximately US$1.9 billion, with growth accelerating sharply in the second half as volumes improved across both the Industrial and Healthcare segments.
Ansell Fundamentals Come In Strong
The FY26 numbers underscored the success of Ansell’s Accelerated Productivity Investment Program, which has now delivered its targeted US$50 million in recurring annual savings. EBIT margins expanded as management demonstrated strong cost discipline despite headwinds from tariffs and geopolitical cost pressures linked to the Middle East conflict. Cash conversion hit 113%, and the company reduced net working capital, leaving the balance sheet in a stronger position.
Management declared a final dividend of US41.5 cents per share, unfranked, bringing the full-year payout to US68.1 cents, a 35% increase year-on-year at a payout ratio of approximately 45%. The company also confirmed it will continue its US$200 million on-market buyback into FY27, having already completed US$118.4 million of repurchases in FY26.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Perhaps most significantly for markets, Ansell guided adjusted EPS for FY27 to a range of US158 to 170 cents, implying solid double-digit growth at the midpoint. The guidance, which came in ahead of consensus expectations, reflects management’s confidence in sustained volume recovery and the benefit of recent price increases implemented to offset input cost inflation.
Downgraded on Valuation Concerns
Yet even as the operational story strengthened, RBC Capital Markets moved to downgrade Ansell from Outperform to Sector Perform, simultaneously lifting its 12-month price target from A$36 to A$38.
The broker’s research note acknowledged that the company delivered an impressive result at the upper end of EPS guidance, demonstrated effective cost management and operating leverage, and provided FY27 guidance that beat market expectations. RBC added that it remains positive on the company’s outlook, driven by robust revenue growth and slight margin expansion, but emphasised that the downgrade reflects stock valuation following the rapid re-rating.
The upgrade to the price target shows that the broker is not turning bearish on the business itself, but rather signalling that the share price has run ahead of near-term fundamental support. With the new A$38 target sitting roughly in line with Monday’s close, RBC is effectively capping expected upside and framing Ansell as a “fully valued” proposition at current levels.
Bull Case:
- FY27 EPS guidance of US158-170c implies continued double-digit earnings growth
- US$50m APIP savings now locked in, driving structural margin expansion
- Strong cash generation funds rising dividends and ongoing US$200m buyback
- Volume recovery accelerating across Industrial and Healthcare segments in H2
- Management demonstrated pricing power despite tariffs and cost inflation pressures
Bear Case:
- Share price up 52% in three months; RBC downgrade signals limited upside
- US$15m Healthcare revenue pulled forward in FY26, flattering the base
- Valuation now stretched after rapid re-rating from post-pandemic trough levels
- Sustaining high-teens EPS growth beyond FY27 may prove challenging if tailwinds fade
- Macro risks remain from tariffs, geopolitical tensions, and industrial cycle uncertainty
